title: Trophinin is a potent prognostic marker of ovarian cancer involved in platinum sensitivity.
abstract: Ovarian cancer is the leading cause of death in women with gynecological malignancies, with prognosis of advanced stage tumors determined by chemotherapeutic response and the success of tumor resection. Since aberrant RAS pathway activation is frequent in ovarian cancer, study of in vitro RAS-induced transformation and accompanying genomic expression changes in ovarian surface epithelial cells is imperative for development of new therapeutic modalities and for understanding tumorigenesis. cDNA microarray analysis revealed TROPHONIN (TRO), a homophilic adhesion molecule involved in blastocyst implantation, was among the genes most downregulated by RAS induction. TRO expression is higher in cisplatin-sensitive cancer cell lines and positively correlates with prognoses in ovarian cancers. TRO knockdown by RNA interference conferred cisplatin resistance and led to increased invasiveness of cultured ovarian cancer cells. These findings underscore the importance of TRO in tumorigenesis, and suggest that TRO may be a useful biomarker for cisplatin sensitivity and invasive potential.
authors.affiliation: Department of Gynecology and Obstetrics, Graduate School of Medicine, Kyoto University, Japan.
authors.forename: Tsukasa
authors.initials: T
authors.lastname: Baba
authors.forename: Seiichi
authors.initials: S
authors.lastname: Mori
authors.forename: Noriomi
authors.initials: N
authors.lastname: Matsumura
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Kariya
authors.forename: Susan K
authors.initials: SK
authors.lastname: Murphy
authors.forename: Eiji
authors.initials: E
authors.lastname: Kondoh
authors.forename: Takashi
authors.initials: T
authors.lastname: Kusakari
authors.forename: Hideki
authors.initials: H
authors.lastname: Kuroda
authors.forename: Masaki
authors.initials: M
authors.lastname: Mandai
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Higuchi
authors.forename: Kenji
authors.initials: K
authors.lastname: Takakura
authors.forename: Michiko N
authors.initials: MN
authors.lastname: Fukuda
authors.forename: Shingo
authors.initials: S
authors.lastname: Fujii
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis*; D015815:Cell Adhesion Molecules / Q000032:analysis*; D002945:Cisplatin / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D009363:Neoplasm Proteins / Q000032:analysis*; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000378:metabolism*; D011379:Prognosis; D015203:Reproducibility of Results; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors; D012680:Sensitivity and Specificity
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D015815:Cell Adhesion Molecules; D009363:Neoplasm Proteins; C093649:TRO protein, human; D002945:Cisplatin